Screening for Brain Cancer: Why (Not)

Alves, José Luís; Santiago, João Gonçalo

doi:10.1016/j.wneu.2014.08.052

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The low prevalence of brain tumors also contributes to a correspondingly low positive predictive value, which would further limit the yield of brain tumor screening. Other authors have reached similar conclusions .…”

Section: Discussionsupporting

confidence: 75%

Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review

et al. 2018

View full text Add to dashboard Cite

Brain tumors comprise 2% of all cancers but are disproportionately responsible for cancer‐related deaths. The 5‐year survival rate of glioblastoma, the most common form of malignant brain tumor, is only 4.7%, and the overall 5‐year survival rate for any brain tumor is 34.4%. In light of the generally poor clinical outcomes associated with these malignancies, there has been interest in the concept of brain tumor screening through magnetic resonance imaging. Here, we will provide a general overview of the screening principles and brain tumor epidemiology, then highlight the major studies examining brain tumor prevalence in asymptomatic populations in order to assess the potential benefits and drawbacks of screening for brain tumors. Implications for Practice Magnetic resonance imaging (MRI) screening in healthy asymptomatic adults can detect both early gliomas and other benign central nervous system abnormalities. Further research is needed to determine whether MRI will improve overall morbidity and mortality for the screened populations and make screening a worthwhile endeavor.

show abstract

Section: Discussionsupporting

confidence: 75%

Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Despite years of research, malignant gliomas remain incurable once detected and is the costliest cancer in terms of hospital care and lost productivity. The possibility of asymptomatic brain tumors has received little discussion in the literature and there is an absence of evidence sustaining the clinical utility of brain tumor identification prior to magnetic resonance imaging (MRI) detectable lesion, in terms of clinical and economic advantages [17]. To date, studies have almost exclusively examined samples drawn from patients in whom the brain tumor is already clinically evident, which makes it difficult to distinguish what is a result of the brain tumor itself versus other effects including brain microenvironment disruption.…”

Section: Discussionmentioning

confidence: 99%

A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stage

et al. 2019

View full text Add to dashboard Cite

Malignant gliomas remain incurable with a poor prognosis despite of aggressive treatment. We have been studying the development of brain tumors in a glioma rat model, where rats develop brain tumors after prenatal exposure to ethylnitrosourea (ENU), and there is a sizable interval between when the first pathological changes are noted and tumors become detectable with MRI. Our aim to define a molecular timeline through proteomic profiling of the cerebrospinal fluid (CSF) such that brain tumor commitment can be revealed earlier than at the presymptomatic stage. A comparative proteomic approach was applied to profile CSF collected serially either before, at and after the time MRI becomes positive. Elastic net (EN) based models were developed to infer the timeline of normal or tumor development respectively, mirroring a chronology of precisely timed, “clocked”, adaptations. These CSF changes were later quantified by longitudinal entropy analyses of the EN predictive metric. False discovery rates (FDR) were computed to control the expected proportion of the EN models that are due to multiple hypothesis testing. Our ENU rat brain tumor dating EN model indicated that protein content in CSF is programmed even before tumor MRI detection. The findings of the precisely timed CSF tumor microenvironment changes at presymptomatic stages, deviation from the normal development timeline, may provide the groundwork for the understanding of adaptation of the brain environment in tumorigenesis to devise effective brain tumor management strategies.

show abstract

Screening for Brain Cancer: Why (Not)

Cited by 2 publications

References 8 publications

Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review

Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review

A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stage

Contact Info

Product

Resources

About